Canaccord raised the firm’s price target on Natera (NTRA) to $180 from $165 and keeps a Buy rating on the shares. The firm previewed its coverage in the Diagnotstics and Tools universe for the year and it believes the outlook appears move favorable in 2025, albeit weighed toward the back end of the year. As the group underperformed in 2024 they acknowledege investors may be weary, but they believe companies with attractive fundamentals, the ability to exceed Street expectations, and important catalysts should outperform in the near term and Natera fits the bill.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Cathie Wood’s Ark Invest Offloads Tesla (TSLA) Shares Worth $63M
- Natera expands patent infringement lawsuit against NeoGenomics
- Natera price target raised to $200 from $160 at JPMorgan
- Natera enrolls 1st patients in SAGITTARIUS clinical trial in colon cancer
- Natera Aligns Executive Chairman’s Pay with Performance